First City Capital Management’s Myriad Genetics MYGN Stock Holding History

First City Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-700	Closed	-$26.2K	–	375
2016 Q1	$26.2K	Hold	700	–	–	0.02%	351
2015 Q4	$30.2K	Hold	700	–	–	0.02%	342
2015 Q3	$26.2K	Hold	700	–	–	0.02%	352
2015 Q2	$23.8K	Hold	700	–	–	0.02%	355
2015 Q1	$24.8K	Hold	700	–	–	0.02%	336
2014 Q4	$23.8K	Hold	700	–	–	0.02%	356
2014 Q3	$27K	Hold	700	–	–	0.02%	327
2014 Q2	$27.2K	Hold	700	–	–	0.02%	345
2014 Q1	$23.9K	Buy	+700	New	+$21.7K	0.02%	354

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

First City Capital Management's MYGN Position: Q2 2016 in Review

First City Capital Management sold out of Myriad Genetics (MYGN) in Q2 2016, closing a stake of 700 shares — an estimated $26.2K sold.

First City Capital Management first reported a position in MYGN in Q1 2014 and held it in 9 quarters. The position peaked at $30.2K in Q4 2015. 252 funds tracked by Wall St. Rank hold MYGN as of Q2 2016.

First City Capital Management reported no remaining Myriad Genetics position as of Q2 2016 after selling out during the quarter.
First City Capital Management sold 700 Myriad Genetics shares in Q2 2016, an estimated $26.2K.
First City Capital Management first reported a position in Myriad Genetics in Q1 2014 and held it in 9 quarters.
First City Capital Management's Myriad Genetics position peaked at $30.2K in Q4 2015.
252 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2016.

Based on First City Capital Management's 13F filing for Q2 2016, filed 16 Aug 2016.